Yumei Li Selected Research

Member 1 Group F Nuclear Receptor Subfamily 1

5/2022

POU6F1 cooperates with RORA to suppress the proliferation of lung adenocarcinoma by downregulation HIF1A signaling pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yumei Li Research Topics

Disease

44	Neoplasms (Cancer) 07/2022 - 07/2010
15	Neoplasm Metastasis (Metastasis) 07/2022 - 10/2013
12	Hypoxia (Hypoxemia) 05/2022 - 02/2009
10	Hepatocellular Carcinoma (Hepatoma) 08/2022 - 01/2014
8	Inflammation (Inflammations) 01/2022 - 01/2016
7	Retinal Diseases 12/2019 - 06/2013
7	Retinitis Pigmentosa (Pigmentary Retinopathy) 01/2019 - 02/2015
6	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 01/2015
5	Melanoma (Melanoma, Malignant) 01/2022 - 02/2017
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 08/2012
4	Retinal Degeneration 01/2022 - 06/2015
4	Aortic Dissection 01/2022 - 10/2020
4	Brain Ischemia (Cerebral Ischemia) 01/2022 - 01/2020
4	Lung Neoplasms (Lung Cancer) 01/2020 - 08/2012
4	Ciliopathies 01/2018 - 03/2015
4	Stomach Neoplasms (Stomach Cancer) 11/2017 - 10/2013
4	Fibrosis (Cirrhosis) 05/2017 - 02/2014
3	Myocarditis (Carditis) 01/2022 - 10/2017
3	Tuberculosis (Tuberculoses) 01/2021 - 01/2020
3	Rupture 10/2020 - 10/2011
3	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2018
3	Liver Neoplasms (Liver Cancer) 02/2019 - 09/2018
3	Retinal Dystrophies 01/2019 - 12/2016
3	Vascular Remodeling 05/2015 - 01/2014
2	Chronic Disease (Chronic Diseases) 01/2022 - 01/2022
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2022 - 01/2020
2	Reperfusion Injury 01/2022 - 06/2021
2	Stroke (Strokes) 12/2021 - 10/2021
2	Spontaneous Abortion (Miscarriage) 12/2021 - 10/2015
2	Insulin Resistance 03/2021 - 01/2021
2	Carcinogenesis 01/2020 - 04/2017
2	Triple Negative Breast Neoplasms 01/2020 - 01/2019
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2020 - 02/2014
2	Cognitive Dysfunction 02/2019 - 02/2015
2	Adenocarcinoma of Lung 03/2018 - 03/2014
2	Disease Progression 01/2018 - 03/2015
2	Pulmonary Arterial Hypertension 05/2017 - 01/2013
2	Cardiomegaly (Heart Hypertrophy) 01/2017 - 12/2014
1	Circulating Neoplastic Cells 07/2022

Drug/Important Bio-Agent (IBA)

31	Proteins (Proteins, Gene)FDA Link 07/2022 - 01/2011
10	Pharmaceutical PreparationsIBA 07/2022 - 08/2012
9	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2014
9	MicroRNAs (MicroRNA)IBA 01/2022 - 07/2013
8	Messenger RNA (mRNA)IBA 01/2022 - 03/2011
8	Retinaldehyde (Retinal)IBA 01/2019 - 02/2015
6	Biological ProductsIBA 08/2022 - 01/2014
5	DNA (Deoxyribonucleic Acid)IBA 05/2022 - 06/2013
5	CateninsIBA 01/2022 - 01/2020
4	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2019
4	CytokinesIBA 11/2021 - 03/2011
4	15-hydroxy-5,8,11,13-eicosatetraenoic acidIBA 01/2016 - 02/2009
3	EnzymesIBA 01/2022 - 10/2018
3	Small Interfering RNA (siRNA)IBA 01/2022 - 09/2018
3	LigandsIBA 01/2022 - 01/2016
3	Melitten (Melittin)IBA 01/2022 - 07/2016
3	AcidsIBA 01/2021 - 02/2009
3	CollagenIBA 01/2020 - 02/2014
3	Bispecific AntibodiesIBA 01/2020 - 01/2018
3	Gemcitabine FDA Link 09/2016 - 03/2015
3	tanshinoneIBA 01/2016 - 01/2012
3	Protein Kinases (Protein Kinase)IBA 02/2015 - 01/2012
2	Transcription Factors (Transcription Factor)IBA 05/2022 - 01/2014
2	Caspase 3 (Caspase-3)IBA 01/2022 - 11/2017
2	Protein Kinase CIBA 01/2022 - 02/2009
2	Oxygen (Dioxygen)IBA 01/2022 - 01/2020
2	SurvivinIBA 01/2022 - 03/2019
2	LipidsIBA 12/2021 - 01/2016
2	Hematoxylin (Haematoxylon)IBA 07/2021 - 01/2014
2	Eosine Yellowish-(YS) (Eosin)IBA 07/2021 - 01/2014
2	Anti-Bacterial Agents (Antibiotics)IBA 05/2021 - 01/2021
2	AntigensIBA 01/2021 - 02/2017
2	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2020
2	Long Noncoding RNAIBA 01/2021 - 01/2021
2	Galectin 3 (LGALS3)IBA 05/2020 - 05/2017
2	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 05/2020 - 12/2017
2	ErbB Receptors (EGF Receptor)IBA 01/2020 - 09/2019
2	InterferonsIBA 01/2020 - 01/2018
2	Antigen-Antibody Complex (Immune Complex)IBA 01/2020 - 07/2012
2	AntibodiesIBA 01/2020 - 01/2018
2	Angiotensin IIIBA 01/2020 - 01/2016
2	RutheniumIBA 02/2019 - 01/2019
2	Fibronectins (Fibronectin)IBA 01/2019 - 02/2014
2	human ERBB2 proteinIBA 04/2018 - 01/2018
2	GTP Phosphohydrolases (GTPases)IBA 01/2018 - 03/2015
2	ChemokinesIBA 01/2016 - 03/2011
2	PDZ-binding kinaseIBA 02/2015 - 11/2013
1	Oral ContraceptivesIBA 07/2022
1	Mifepristone (RU 486)FDA Link 07/2022
1	Abortifacient Agents (Abortifacients)IBA 07/2022
1	GoldIBA 05/2022

Therapy/Procedure

18	Therapeutics 07/2022 - 01/2013
9	Drug Therapy (Chemotherapy) 07/2022 - 08/2012
3	Immunotherapy 07/2022 - 01/2018
3	Artificial Respiration (Mechanical Ventilation) 01/2022 - 01/2021
3	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2022 - 01/2019
2	Radiotherapy 06/2020 - 01/2020
1	Chemoprevention 07/2022
1	Play Therapy (Therapy, Play) 07/2022
1	Biological Therapy 05/2022
1	Lasers (Laser) 05/2022